Xiao-Qin Duan

HBsAg (−)/HBsAb (−)/HBeAg (−)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B‐cell lymphoma receiving rituximab based immunochemotherapy

Lin Liu, Xiao-Hua Luo, Li Wang, 2023, Journal of medical virology.